Skip to main content
OpenTrials
Completed

NCT Number: NCT02194127

Efficacy and Tolerability of a Bilberry Extract in Volunteers With Impaired Twilight and Night Vision

Study to determine the efficacy of Anthocyan to improve impaired twilight and night vision and to test its tolerability and safety.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

50 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects (volunteers) with age-related impaired twilight and night
  • Age 50 to 70, men or women
  • Written informed consent
  • Full visual acuity (vision ≥ 0.7) according to DIN Standard condition
  • Refraction ≤ +/-6.0 in the highest main step
  • Age-related findings in the ophthalmologic examination (anterior chamber and eye ground)
  • Normal intraocular pressure (10-20 mmHg)

Exclusion criteria

  • Diabetes mellitus
  • Epilepsy
  • Abnormal visual acuity or eye ground (e.g. clouding of the lens)
  • Age related vision problems
  • Glaucoma and macular degeneration
  • Disease of the retina
  • Consumption of anthocyan preparations during the past six months
  • Opthalmologic pathology: cataract, visus < 0.7, retinal pathology, maculopathy, intraocular pressure (> 21 mmHg), known acute or chronic eye disease, use of hard contact lenses, eye surgery performed within the last 12 months
  • Any serious disorder that might interfere with his/her participation in this study and the evaluation of the efficacy or safety of the test drug: e.g. diabetes mellitus, anamnestic indications of diabetic microangiopathy or polyneuropathy, renal insufficiency, hepatic or metabolic dysfunction, cardiovascular disease (hypertension > 160/100 mmHg), psychiatric disorder, myasthenia gravis, delirious state, albino
  • Any treatment that might interfere with the evaluation of the test drug, in particular drugs with known influence on eye sight or adaptation (e.g. chloroquine, digitalis, ethambutol, chlorpromazine or phenothiazine derivatives such as thioridazine, periciazine, perphenazine)
  • Known hypersensitivity to any of the ingredients of the study drug
  • Drug and alcohol abuse
  • Pregnancy, lactation, women of childbearing potential who do not use an established contraceptive
  • Participation in another trial within the past 30 days

Treatment and study plan

Anthocyan capsules

Drug

Placebo

Drug

Primary outcomes

  1. Measurement of the maximum velocity of dilatation of the pupil

    Time frame: day 29

Secondary outcomes

  1. Measurement of the maximum velocity of dilatation of the pupil

    Time frame: Days 1 and 8

  2. Measurement of the initial pupil diameter

    Time frame: days 1, 8 and 29

  3. Measurement of the latency time

    Time frame: Days 1, 8 and 29

  4. Measurement of the absolute and relative constriction amplitude

    Time frame: Days 1, 8 and 29

  5. Measurement of maximum velocity of contraction

    Time frame: Days 1, 8 and 29

  6. Measurement of velocity of contraction 2

    Time frame: Days 1, 8 and 29

  7. Measurement of initial minimal contrast level

    Time frame: Days 1, 8 and 29

    Determined with Gecko Contrast card

  8. Time to regain contrast vision at one level above the initial minimal contrast

    Time frame: days 1, 8 and 29

    Determined with Gecko Contrast card

  9. Measurement of contrast threshold level at illumination 0.1 cd/m2 with glare

    Time frame: Days 1, 8 and 29

    determined with Mesoptometer II

  10. Measurement of contrast threshold level at illumination 0.032 cd/m2 without glare

    Time frame: Days 1, 8 and 29

    determined with Mesoptometer II

  11. Recovery time after dazzling

    Time frame: Days 1, 8 and 29

  12. Change of potential (µVolt) in retina due to photo activation

    Time frame: Baseline, days 1, 8 and 29

    Measured with Standard Electroretinography (ERG)

  13. Assessment of subjective efficacy based on a visual analogue scale (VAS) rating questionnaire

    Time frame: Pre-dose and days 1, 8 and 29

  14. Assessment of clinical global impression on a 5-point rating scale

    Time frame: Day 29

  15. Number of patients with adverse events

    Time frame: up to day 29

  16. Number of patients with significant changes in laboratory parameters

    Time frame: Baseline and day 29

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Official study title

Efficacy and Tolerability of a Treatment Over 28 Days With a Bilberry Extract Standardised to a Content of 25% Anthocyanidines in Volunteers With Impaired Twilight and Night Vision

Important dates

Study start
1998
Primary completion
1999
First posted
Jul 18, 2014
Registry last updated
Jul 24, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.